Loading institutional data...
Loading institutional data...
Held by 1,569 of 5,944 reporting institutions (99th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $93.44 today, the market must believe free cash flow compounds 18.7%/yr for a decade (off $1.9B normalized FCF).
The market's 18.7% is more optimistic than its 9-yr track record.
2-stage DCF · 0.84B shares · net debt $5.8B
mean 10.7% · volatility σ 44% · implied rate exceeded in 2/9 yrs
Central path = implied 18.7%/yr growth; shaded band = ±1σ (44%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash conversion lags reported earnings — watch accruals. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $2.1B buybacks = $2.1B returned on $1.6B FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 48%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $194M is below the $1.9B due within a year — relies on refinancing or operating cash flow. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~3.9% on $6.0B of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-08-05
Where each multiple sits in its own 14-yr range · 100th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 47.2 | 46.9 | 47.6 | 47.3 | 48.8 | 48.7 | 48.8 | 48.4 |
| Gross Profit | 52.8 | 53.1 | 52.4 | 52.7 | 51.2 | 51.3 | 51.2 | 51.6 |
| SG&A | 33.8 | 34.2 | 31.6 | 30.8 | 30.7 | 31.1 | 31.7 | 32.1 |
| Operating Income | 19.0 | 18.9 | 20.8 | 21.9 | 20.5 | 20.2 | 19.5 | 19.5 |
| Income Tax | 3.9 | 3.9 | 4.4 | 4.6 | 4.3 | 4.2 | 3.9 | 3.9 |
| Net Income | 13.9 | 13.7 | 15.1 | 16.2 | 15.1 | 14.8 | 14.3 | 14.3 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ORLY: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-08-05 · 16d old
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.78B 100.0% | $16.71B 100.0% | $15.81B 100.0% | $14.41B 100.0% | $13.33B 100.0% | $11.60B 100.0% | $10.15B 100.0% | $9.54B 100.0% | $8.98B 100.0% | $8.59B 100.0% |
| Cost of Revenue | $8.61B 48.4% | $8.15B 48.8% | $7.71B 48.7% | $7.03B 48.8% | $6.31B 47.3% | $5.52B 47.6% | $4.76B 46.9% | $4.50B 47.2% | $4.26B 47.4% | $4.08B 47.5% |
| Cost of Products | — | — | — | — | — | — | — | — | $4.26B 47.4% | $4.08B 47.5% |
| Gross Profit | $9.17B 51.6% | $8.55B 51.2% | $8.10B 51.3% | $7.38B 51.2% | $7.02B 52.7% | $6.09B 52.4% | $5.39B 53.1% | $5.04B 52.8% | $4.72B 52.6% | $4.51B 52.5% |
| Selling, General & Admin | $5.71B 32.1% | $5.30B 31.7% | $4.92B 31.1% | $4.43B 30.7% | $4.10B 30.8% | $3.67B 31.6% | $3.47B 34.2% | $3.22B 33.8% | $3.00B 33.4% | $2.81B 32.7% |
| Operating Income | $3.46B 19.5% | $3.25B 19.5% | $3.19B 20.2% | $2.95B 20.5% | $2.92B 21.9% | $2.42B 20.8% | $1.92B 18.9% | $1.82B 19.0% | $1.73B 19.2% | $1.70B 19.8% |
| Interest Expense | $235.1M 1.3% | $222.5M 1.3% | $201.7M 1.3% | $157.7M 1.1% | $144.8M 1.1% | $161.1M 1.4% | $140.0M 1.4% | $122.1M 1.3% | $91.3M 1.0% | $70.9M 0.8% |
| Other Income (Expense), net | -$220.4M -1.2% | -$206.1M -1.2% | -$181.6M -1.1% | -$155.8M -1.1% | -$135.3M -1.0% | -$152.9M -1.3% | -$130.4M -1.3% | -$121.1M -1.3% | -$87.6M -1.0% | -$62.0M -0.7% |
| Pretax Income | $3.24B 18.2% | $3.05B 18.2% | $3.00B 19.0% | $2.80B 19.4% | $2.78B 20.9% | $2.27B 19.5% | $1.79B 17.6% | $1.69B 17.8% | $1.64B 18.2% | $1.64B 19.1% |
| Income Tax Expense | $702.0M 3.9% | $658.4M 3.9% | $658.2M 4.2% | $626.0M 4.3% | $617.2M 4.6% | $514.1M 4.4% | $399.3M 3.9% | $369.6M 3.9% | $504.0M 5.6% | $599.5M 7.0% |
| Net Income | $2.54B 14.3% | $2.39B 14.3% | $2.35B 14.8% | $2.17B 15.1% | $2.16B 16.2% | $1.75B 15.1% | $1.39B 13.7% | $1.32B 13.9% | $1.13B 12.6% | $1.04B 12.1% |
| Per Share | ||||||||||
| EPS (Basic) | $2.98 | $2.73 | $2.59 | $33.75 | $31.39 | $23.74 | $18.07 | $16.27 | $12.82 | $10.87 |
| EPS (Diluted) | $2.97 | $2.71 | $2.56 | $33.44 | $31.10 | $23.53 | $17.88 | $16.10 | $12.67 | $10.73 |
| Weighted Avg Shares (Basic) | 851.5M | 875.1M | 907.1M | 64.4M | 69.0M | 73.8M | 77.0M | 81.4M | 88.4M | 95.4M |
| Weighted Avg Shares (Diluted) | 855.9M | 880.6M | 915.0M | 65.0M | 69.6M | 74.5M | 77.8M | 82.3M | 89.5M | 96.7M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 496 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMZN | $2.93T | — | — | — | — | — | — | 20.5% | 16.2% | — | 5,764 |
| TSLA | $1.21T | 297.7× | 127.6× | 12.7× | -2.9% | 18.0% | 4.0% | 4.6% | 4.2% | 0.9× | 4,029 |
| PDD | $517.8B | 38.5× | 37.5× | 8.4× | -84.3% | 56.3% | 22.7% | 23.7% | 23.7% | — | 548 |
| HD | $351.7B | 24.8× | 16.4× | 2.1× | 3.2% | 33.3% | 8.6% | 111% | 22.8% | 2.0× | 3,970 |
| TOYOF | $242.7B | — | — | — | — | — | — | — | — | — | 4 |
| TJX | $177.0B | 32.8× | — | 2.9× | 7.1% | 31.0% | 9.1% | 53.9% | 45.6% | — | 2,608 |
| LOW | $123.4B | 18.6× | 13.1× | 1.4× | 3.1% | 33.5% | 7.7% | -67.1% | 22.3% | 3.2× | 2,591 |
| SBUX | $120.5B | 65.0× | 28.7× | 3.2× | 2.8% | — | 5.0% | -22.9% | 28.7% | 3.1× | 2,252 |
| MELI | $97.5B | 48.8× | — | 3.4× | 39.1% | 44.5% | 6.9% | 29.6% | 12.5% | — | 1,380 |
| MAR | $96.1B | 38.0× | 22.3× | 3.7× | 4.3% | — | 9.9% | -69.0% | -69.4% | 0.0× | 1,559 |
| LKNCY | $94.1B | 183.4× | 99.1× | 13.4× | -79.6% | — | 7.3% | 23.0% | 23.0% | 0.0× | 9 |
| ABNB | $93.5B | — | 33.9× | 7.6× | 10.3% | 83.0% | 20.5% | 30.6% | 30.6% | 0.0× | 1,246 |
| RCL | $88.7B | 21.0× | — | 5.0× | 8.8% | 49.4% | 23.8% | 42.5% | 12.3% | — | 1,114 |
| ROST | $81.6B | 38.3× | 24.3× | 3.6× | 7.7% | 27.7% | 9.4% | 34.7% | 29.8% | 0.3× | 1,276 |
| GM | $80.6B | 27.3× | 4.0× | 0.4× | -1.3% | — | 1.5% | 4.5% | 4.5% | — | 1,447 |
| ORLY | $78.7B | 31.5× | 21.3× | 4.4× | 6.4% | 51.6% | 14.3% | -333% | 48.3% | 1.5× | 1,569 |
| HLT | $74.8B | 53.0× | 25.7× | 6.2× | 7.7% | — | 12.1% | -27.0% | -27.0% | — | 1,126 |
| RACE | $71.5B | — | — | — | — | — | — | — | — | — | 690 |
| SE | $70.4B | 45.6× | 28.1× | 3.1× | 36.4% | 44.7% | 6.9% | 12.6% | 12.6% | — | 718 |
| NKE | $63.0B | 20.2× | — | 1.4× | 0.2% | 42.9% | 6.7% | 20.9% | 14.9% | — | 1,848 |
| AZO | $51.4B | 21.1× | 14.2× | 2.7× | 2.4% | 52.6% | 13.2% | -73.2% | 46.4% | 2.1× | 1,245 |
| EBAY | $49.9B | 25.6× | 18.1× | 4.5× | 7.9% | 71.5% | 18.3% | 45.3% | 38.8% | 0.3× | 1,182 |
| VIK | $48.3B | — | — | — | — | — | — | — | — | — | 479 |
| CMG | $46.1B | 30.3× | 19.9× | 3.9× | 5.4% | — | 12.9% | 54.3% | 54.3% | 0.0× | 1,203 |
| DHI | $44.6B | 13.1× | — | 1.3× | -6.9% | 23.7% | 10.5% | 14.8% | 14.8% | — | 1,092 |
Peers = companies sharing ORLY's sector (Consumer Cyclical) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.